A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor MK-1775 for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN
This is a phase 2 study to see how useful investigational drug MK-1775 in combination with
cisplatin is compared to cisplatin alone in patients with recurrent or metastatic squamous
cell carcinoma of the head and neck.
Chemotherapy is toxic to tumour cells. It prevents the tumour cells from multiplying by
damaging their DNA, which in turn stops the tumour from growing. However, a protein, called
Wee1, may play a role in helping to repair damaged tumour cells, so that the tumour continues
MK-1775 is a new drug which may block Wee1 protein activity. When given in combination with
chemotherapy drug cisplatin, MK-1775 may help prevent the Wee1 protein from repairing
damaged tumour cells without causing harm to normal cells. This is believed to increase the
effectiveness of cisplatin.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society